Cora Schlesinger
Growth, contrarian, long only

GTX Incorporated: Its 'Other' Drug, Capesaris

GTx Inc. (NASDAQ:GTXI) is a Memphis-based biopharmaceutical company founded in 1997 with a pipeline of synthetic small, hormone-mimic type drugs, the "selective androgen receptor modulators" (SARMs) and "selective estrogen receptor modulators" (SERMs). Today, a SERM, Capesaris (GTX-758), currently in a Phase IIb clinical trial (G200712), is discussed. It has been in 8 previous clinical trials. Capesaris is a SERM α-agonist under development for first- or second-line treatment of advanced or metastatic prostate cancers, i.e., Stages III and IV, here abbreviated as "m-PCA." The treatment goal for m-PCA is total systemic (body wide) androgen suppression or blockade, referred to as (surgical or chemical) castration. GTx's lead drug, enobosarm, was discussed in 2 previous articles. The second...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details